Health insurers, like airplanes, need ‘black box recorders’

When two Boeing 737 Max airplanes crashed within the span of six months of each other, killing 346 people, black box recorders helped investigators find the cause. A similar kind of black box should be available to alert regulators, lawmakers, or the public to deaths due to health insurance company behavior.

Medication Assistance Programs & Barriers to Treatment


People living with migraine often bear a financial burden and can be routinely denied when trying to access treatments, especially the most recently approved class of drugs, CGRPs. I connected with Lindsay Videnieks, the Executive Director of the Headache and Migraine Policy Forum (HMPF) in order to get some answers on what people in the migraine community can do when they’re facing barriers to their migraine treatment.

Acceptance, Compliance With Migraine Drugs Higher With Two Dosing Options

A recent survey of adult migraine sufferers supports a commonly held belief among physicians that multiple dosing options will lead to an increase in compliance with new migraine medications, according to a study recently published in The Journal of Headache and Pain.

New Report Addresses Distinct Challenges in Utilizing ICER to Assess Value of Rare Disease Treatments

BOSTON, MA – Today, Pioneer Institute released a new report, Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies, that examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.

A Year After Approval, Migraine Drugs Are Changing Lives. But Insurance Battles Are Creating a Whole New Headache

Last May, the Food and Drug Administration (FDA) approved Amgen and Novartis’ Aimovig, the first drug specifically designed to prevent chronic migraines, and offered new hope to the millions of Americans regularly weathering these debilitating headaches. Just months later came two other drugs in its class, Eli Lilly’s Emgality and Teva Pharmaceuticals’ Ajovy.